Valneva SE (VALN) EBITDA Margin (2021 - 2026)
Valneva SE (VALN) posted EBITDA Margin of 58.89% for Q1 2026, down 4.49% sequentially from 56.36% in Q4 2025, and down 5767.0% YoY from 1.04% in Q1 2025.
Powered by 
Analysis
Valneva SE (VALN) EBITDA Margin (2021 - 2026) Analysis & Trends
Valneva SE has reported EBITDA Margin for 6 years, with the latest figure at 58.89% in Q1 2026.
- Quarterly EBITDA Margin fell 5767.0% year-over-year to 58.89% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 55.66% (down 3292.0% YoY) and the FY2025 annual result came in at 37.62%, down 5777.0% from the prior year.
- EBITDA Margin fell to 58.89% in Q1 2026 per VALN's latest filing, from 56.36% in the prior quarter.
- Over five years, EBITDA Margin peaked at 34019.26% in Q4 2022 and troughed at 24145.7% in Q3 2022.
- A 5-year average of 547.8% and a median of 44.14% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin soared 3395593 bps in 2022, then sank 3406509 bps in 2023.
- Over 5 years, EBITDA Margin stood at 34019.26% in 2022, then slumped by 100 bps to 45.82% in 2023, then jumped by 33 bps to 30.91% in 2024, then sank by 82 bps to 56.36% in 2025, then slipped by 4 bps to 58.89% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 58.89%, 56.36%, and 145.16% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | -62.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -62.68% |
| Mar 31, 2026 | -58.89% |
| Dec 31, 2025 | -45.50% |
| Sep 30, 2025 | -107.79% |
| Jun 30, 2025 | -11.17% |
| Mar 31, 2025 | -1.22% |
| Dec 31, 2024 | -29.66% |
| Sep 30, 2024 | -16.50% |
| Jun 30, 2024 | -44.25% |
| Mar 31, 2024 | 222.88% |
| Dec 31, 2023 | -45.82% |
| Sep 30, 2023 | -46.50% |
| Jun 30, 2023 | -39.76% |
| Mar 31, 2023 | -36.71% |
| Dec 31, 2022 | 34,019.26% |
| Sep 30, 2022 | -24,145.70% |
| Jun 30, 2022 | -171.90% |
| Mar 31, 2022 | -60.88% |
| Dec 31, 2021 | 63.33% |
| Sep 30, 2021 | -677.70% |